Published in Proc Natl Acad Sci U S A on January 25, 2006
Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A (2010) 1.96
Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol (2009) 1.69
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther (2010) 1.27
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
Smallpox vaccines: targets of protective immunity. Immunol Rev (2011) 1.21
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog (2007) 1.20
In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother (2008) 1.19
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol (2007) 1.19
Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci U S A (2009) 1.14
Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J Virol (2008) 1.08
Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine (2009) 1.08
Probing the functional heterogeneity of surface binding sites by analysis of experimental binding traces and the effect of mass transport limitation. Biophys J (2006) 1.06
Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol (2011) 1.05
Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir Ther (2010) 1.02
Antibodies for biodefense. MAbs (2011) 1.02
Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation. J Virol (2008) 1.02
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology (2007) 1.00
Antibody responses to vaccinia membrane proteins after smallpox vaccination. J Infect Dis (2007) 0.99
Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis. J Virol (2013) 0.99
Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS One (2011) 0.92
Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J Virol (2011) 0.91
Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach. Antiviral Res (2008) 0.91
Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure. J Struct Biol (2012) 0.89
Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule. Proc Natl Acad Sci U S A (2010) 0.88
Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virol (2008) 0.88
Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov (2009) 0.88
Epitope-distal effects accompany the binding of two distinct antibodies to hepatitis B virus capsids. J Am Chem Soc (2013) 0.86
Bayesian analysis of heterogeneity in the distribution of binding properties of immobilized surface sites. Langmuir (2008) 0.86
Protective murine and human monoclonal antibodies against eczema vaccinatum. Antivir Ther (2011) 0.83
Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease. Virol J (2011) 0.83
Assessment of differences in the conformational flexibility of hepatitis B virus core-antigen and e-antigen by hydrogen deuterium exchange-mass spectrometry. Protein Sci (2014) 0.81
Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies. PLoS One (2012) 0.80
Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines. Clin Vaccine Immunol (2007) 0.79
Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections. Viruses (2010) 0.76
Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease. PLoS One (2015) 0.75
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A (1991) 5.94
The looming threat of bioterrorism. Science (1999) 5.58
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol (1994) 4.67
An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol (1971) 4.61
Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol (1980) 4.24
Studies smallpox and complications of smallpox vaccination. Pediatrics (1960) 3.87
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol (1992) 3.24
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature (1984) 3.03
A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology (1992) 2.67
The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology (1993) 2.66
Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J Virol (1993) 2.64
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol (1992) 2.60
The human immunoglobulin VH repertoire. Immunol Today (1995) 2.60
Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis (2003) 2.46
Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus. J Gen Virol (1971) 2.35
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology (1999) 2.15
Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol (1998) 2.14
Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol (1990) 1.94
Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion. J Gen Virol (1998) 1.81
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J Gen Virol (2002) 1.59
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest (2005) 1.50
Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res (2001) 1.50
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol (2000) 1.48
An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol (2005) 1.45
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis (2004) 1.40
Screening of phage antibody libraries. Methods Enzymol (1996) 1.39
Neutralizing activities of antisera to poxvirus soluble antigens. J Gen Virol (1974) 1.36
Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv Exp Med Biol (1998) 1.32
Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology (2001) 1.32
Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers. Clin Infect Dis (2004) 1.27
An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine (2004) 1.15
The efficacy of vaccinial immune globulin. A 15-year study. Vox Sang (1976) 1.07
Potential of primate monoclonal antibodies to substitute for human antibodies: nucleotide sequence of chimpanzee Fab fragments. Hum Antibodies Hybridomas (1990) 1.04
Production of monoclonal antibodies in COS and CHO cells. Curr Opin Biotechnol (1995) 0.92
Monkeypox in the United States. Contemp Top Lab Anim Sci (2003) 0.81
Four chimpanzee monoclonal antibodies isolated by phage display neutralize hepatitis a virus. Virology (2002) 0.79
Crystal structure of glycoprotein B from herpes simplex virus 1. Science (2006) 5.57
Ebola 2014--new challenges, new global response and responsibility. N Engl J Med (2014) 5.23
Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci (2002) 4.86
Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J (2006) 4.06
Sedimentation equilibrium analysis of protein interactions with global implicit mass conservation constraints and systematic noise decomposition. Anal Biochem (2004) 3.71
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem (2003) 3.70
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe (2007) 2.97
Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J (2005) 2.95
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Studying multiprotein complexes by multisignal sedimentation velocity analytical ultracentrifugation. Proc Natl Acad Sci U S A (2004) 2.74
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Recorded scan times can limit the accuracy of sedimentation coefficients in analytical ultracentrifugation. Anal Biochem (2013) 2.57
Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol (2010) 2.45
Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling. Protein Sci (2007) 2.44
Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. Proc Natl Acad Sci U S A (2007) 2.43
Sedimentation velocity analysis of heterogeneous protein-protein interactions: Lamm equation modeling and sedimentation coefficient distributions c(s). Biophys J (2005) 2.39
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles. Methods Enzymol (2004) 2.24
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA (2005) 2.21
Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc Natl Acad Sci U S A (2002) 2.19
Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem (2003) 2.19
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1. Nat Struct Mol Biol (2006) 2.10
Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci U S A (2005) 2.09
Herpes simplex virus glycoproteins gB and gH function in fusion between the virion envelope and the outer nuclear membrane. Proc Natl Acad Sci U S A (2007) 2.07
Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J Virol (2005) 2.07
Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 2.06
Structure and assembly mechanism for heteromeric kainate receptors. Neuron (2011) 2.03
Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM). J Virol (2002) 2.03
Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis (2008) 2.00
Sedimentation velocity analysis of heterogeneous protein-protein interactions: sedimentation coefficient distributions c(s) and asymptotic boundary profiles from Gilbert-Jenkins theory. Biophys J (2005) 2.00
Characterizing protein-protein interactions by sedimentation velocity analytical ultracentrifugation. Curr Protoc Immunol (2008) 1.97
Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol (2006) 1.94
Protein composition of the vaccinia virus mature virion. Virology (2006) 1.93
Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry. J Virol (2003) 1.92
High-precision isothermal titration calorimetry with automated peak-shape analysis. Anal Chem (2012) 1.92
Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J Virol (2010) 1.91
The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry. Proc Natl Acad Sci U S A (2004) 1.89
Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncology (2005) 1.89
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol (2005) 1.86
Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol (2005) 1.85
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus. Chem Biol (2011) 1.80
Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem (2002) 1.79
Mutational evidence of internal fusion loops in herpes simplex virus glycoprotein B. J Virol (2007) 1.79
Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface. J Virol (2003) 1.78
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
On the distribution of protein refractive index increments. Biophys J (2011) 1.76
Discovery of antivirals against smallpox. Proc Natl Acad Sci U S A (2004) 1.76
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
The N-terminal domain of GluR6-subtype glutamate receptor ion channels. Nat Struct Mol Biol (2009) 1.73
The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol (2005) 1.73
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A (2010) 1.72
Raccoon rabies virus variant transmission through solid organ transplantation. JAMA (2013) 1.71
Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol (2010) 1.70
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Conformational restriction blocks glutamate receptor desensitization. Nat Struct Mol Biol (2006) 1.67
Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops. J Virol (2009) 1.65
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol (2004) 1.62
Role of the I7 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol (2004) 1.59
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions. J Virol (2007) 1.56
Tanapox infection in a college student. N Engl J Med (2004) 1.56
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55
External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. J Cell Biol (2005) 1.55
Measuring protein-protein interactions by equilibrium sedimentation. Curr Protoc Immunol (2007) 1.54
Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b). Nat Immunol (2003) 1.54
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem (2002) 1.53
Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog (2011) 1.53
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology (2007) 1.52
Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences. Biochemistry (2004) 1.52
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
Cooperative interactions at the SLP-76 complex are critical for actin polymerization. EMBO J (2010) 1.45
Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol (2006) 1.45
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44